QUESTIONS26th Annual New Treatments in Chronic Liver Disease
Venue: Hyatt Regency La Jolla
Location: La Jolla, California, United States
| Event Date/Time: Mar 26, 2011 | End Date/Time: Mar 27, 2011 |
Report as SpamDescription
Educational Objectives
After participating in this course, attendees should be able to:
• Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the condition.
• Integrate the algorithm for a therapeutic approach to treatment of HBV using new drugs.
• Discuss novel therapies for HCV including new interferons, immunomodulators, protease and polymerase inhibitors.
• Update the skills and management required for transplant hepatology.
• Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
• Discuss new treatment paradigms for HCV direct-acting antiviral drugs.
• Recognizing the impact of NAFLD and NASH in the US and consider new treatment options for these patients.
• Describe the diagnosis and treatment of PSC, PBC and cholangiocarcinoma.
• Review non-invasive measurement of hepatic fibrosis to replace liver biopsies.
• Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
• Discuss the issues complicating drug treatment in decompensated hepatic C, hepatic encephalopathy and acute alcoholic hepatitis.
2011 Conference Highlights
• Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
• Controversies presented on the treatment of Decompensated HCV, Acute Alcoholic Hepatitis and Hepatic Encephalopathy.
• Audience Response System incorporated for instant feedback and interactive learning.
• Endorsed by the American College of Gastroenterology
• Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.
Scripps Health designates this live activity for a maximum number of 9.75 AMA PRA Category 1 Credit(s)â„¢. Physicians should only claim credit commensurate with the extent of their participation in the activity.
After participating in this course, attendees should be able to:
• Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the condition.
• Integrate the algorithm for a therapeutic approach to treatment of HBV using new drugs.
• Discuss novel therapies for HCV including new interferons, immunomodulators, protease and polymerase inhibitors.
• Update the skills and management required for transplant hepatology.
• Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
• Discuss new treatment paradigms for HCV direct-acting antiviral drugs.
• Recognizing the impact of NAFLD and NASH in the US and consider new treatment options for these patients.
• Describe the diagnosis and treatment of PSC, PBC and cholangiocarcinoma.
• Review non-invasive measurement of hepatic fibrosis to replace liver biopsies.
• Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
• Discuss the issues complicating drug treatment in decompensated hepatic C, hepatic encephalopathy and acute alcoholic hepatitis.
2011 Conference Highlights
• Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
• Controversies presented on the treatment of Decompensated HCV, Acute Alcoholic Hepatitis and Hepatic Encephalopathy.
• Audience Response System incorporated for instant feedback and interactive learning.
• Endorsed by the American College of Gastroenterology
• Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.
Scripps Health designates this live activity for a maximum number of 9.75 AMA PRA Category 1 Credit(s)â„¢. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Venue
Additional Information
For Additional Information
Scripps Conference Services & CME
Email med.edu@scrippshealth.org
Phone 858-652-5400
Fax 858-652-5565
Visit www.scripps.org/conferenceservices
